Experienced in Celiac Disease

Dr. Helen L. Stacey

Internal Medicine
2255 Ygnacio Valley Rd, Suite A, 
Walnut Creek, CA 
Experienced in Celiac Disease
2255 Ygnacio Valley Rd, Suite A, 
Walnut Creek, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Helen Stacey is a primary care provider, practicing in Internal Medicine in Walnut Creek, California. Dr. Stacey is rated as an Experienced provider by MediFind in the treatment of Celiac Disease. Her top areas of expertise are Malabsorption, Strep Throat, Celiac Disease, and Meningitis.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 2 clinical trials in the study of Celiac Disease.

Specialties
Internal Medicine
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

2255 Ygnacio Valley Rd, Suite A, Walnut Creek, CA 94598

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drug: KAN-101
Study Phase: Phase 1
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: LY3437943, Dulaglutide
Study Phase: Phase 2
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
Enrollment Status: Completed
Publish Date: July 08, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Biological
Study Drug: Nexvax2
Study Phase: Phase 2
Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer
Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer
Enrollment Status: Completed
Publish Date: August 31, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 10 Less Clinical Trials

6 Total Publications

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age.
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age.
Journal: Vaccines
Published: November 26, 2024
Similar Doctors
Experienced in Celiac Disease
Dr. Mary R. Sears
Internal Medicine
Experienced in Celiac Disease
Dr. Mary R. Sears
Internal Medicine
140 Brookwood Rd, Suite 201, 
Orinda, CA 
 (8.8 miles away)
925-254-9090
Languages Spoken:
English
See accepted insurances

Mary Sears is a primary care provider, practicing in Internal Medicine in Orinda, California. Dr. Sears is rated as an Advanced provider by MediFind in the treatment of Celiac Disease. Her top areas of expertise are Essential Pentosuria, Renal Glycosuria, Hyperglycerolemia, and Lactate Dehydrogenase Deficiency.

David H. Lehman
Experienced in Celiac Disease
Dr. David H. Lehman
Internal Medicine
Experienced in Celiac Disease
Dr. David H. Lehman
Internal Medicine
5025 J St., Suite 315, 
Sacramento, CA 
 (54.8 miles away)
916-452-1294
Languages Spoken:
English
See accepted insurances

David Lehman is a primary care provider, practicing in Internal Medicine in Sacramento, California. Dr. Lehman is rated as a Distinguished provider by MediFind in the treatment of Celiac Disease. His top areas of expertise are Glossitis, Pernicious Anemia, Urinary Tract Infection in Children, and Urinary Tract Infection (UTI).

Experienced in Celiac Disease
Dr. Leslie S. Tim
Internal Medicine
Experienced in Celiac Disease
Dr. Leslie S. Tim
Internal Medicine

University Healthcare Alliance

1300 Crane St, 
Menlo Park, CA 
 (33.5 miles away)
650-498-6500
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leslie Tim is a primary care provider, practicing in Internal Medicine in Menlo Park, California. Dr. Tim has been practicing medicine for over 44 years and is rated as an Advanced provider by MediFind in the treatment of Celiac Disease. Her top areas of expertise are Juvenile Primary Osteoporosis, Breast Cancer, High Cholesterol, and COVID-19.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stacey's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile